Chiron FGF-2 CAD Therapy Phase II Trial Shows Efficacy In Older Patients
This article was originally published in The Gray Sheet
Executive Summary
Phase II data from Chiron's FGF-2 initializing revascularization support trial (FIRST) for the recombinant fibroblast growth factor-2 protein therapy in no-option coronary artery disease (CAD) patients show achievement of the primary efficacy endpoint of increased exercise capacity at 90 days in older patients, investigators report.